Ketamine Therapy Clinics in the United States: 2026 Statistical Analysis

Original data analysis of the ketamine therapy provider landscape across all 50 states and DC, compiled from the Spravato REMS registry and ASKP member directory.

Data compiled and analyzed by DrugsRegistry.com · Published April 16, 2026 · Licensed under CC BY 4.0

Key Findings

As of July 2026, this directory contains 4,118 source records across 51 states and the District of Columbia in the United States. Of these, 3,816 (92.7%) are current outpatient Spravato locator records, and 302 (7.3%) are current ASKP directory records. One organization can appear in both sources, so these figures should not be interpreted as a count of unique businesses. California leads in total records (389), while Nebraska has the highest per-capita density at 33.5 records per million residents.

Contents

  1. Data Sources and Methodology
  2. National Overview
  3. Providers by State
  4. Clinic Density Per Capita
  5. Top Cities
  6. Provider Specialties
  7. Data Source Breakdown
  8. How to Cite

1. Data Sources and Methodology

This analysis draws on two primary data sources:

  1. Spravato REMS Registry — The FDA-mandated Risk Evaluation and Mitigation Strategy registry of healthcare facilities certified to administer Spravato (esketamine) nasal spray. This registry is maintained by Janssen Pharmaceuticals and the FDA. It contains 3,816 certified treatment centers.
  2. ASKP Member Directory — The American Society of Ketamine Physicians, Psychotherapists, and Practitioners (ASKP) maintains a directory of its member clinics. This directory contains 302 member practices.

Records were cross-referenced using provider name, address, and NPI (National Provider Identifier) number to identify overlapping entries. 0 providers appear in both sources. After deduplication, the combined dataset contains 4,118 unique providers.

Provider credentials and specialties were verified against the CMS NPI Registry (NPPES) when NPI numbers were available. Population estimates are based on U.S. Census Bureau 2024 estimates.

This data represents certified and registered providers only. The actual number of practitioners offering ketamine therapy in the United States may be higher, as some providers administer ketamine without ASKP membership or Spravato certification (e.g., anesthesiologists providing off-label IV ketamine infusions).

2. National Overview

4,118 ketamine therapy providers across 51 states and DC

MetricCountPercentage
Total unique providers4,118100%
Spravato REMS-certified centers3,81692.7%
ASKP member clinics3027.3%
Listed in both registries00.0%
Spravato-only (not ASKP)3,81692.7%
ASKP-only (not Spravato-certified)3027.3%
States with at least one provider51100% of states

The dominance of Spravato REMS-certified centers (92.7% of all providers) reflects the growth of the FDA-approved pathway since esketamine’s approval in March 2019. ASKP member clinics, which more commonly offer IV ketamine infusions and ketamine-assisted psychotherapy (KAP), represent a smaller but clinically significant segment of the market.

3. Providers by State

All 51 states and the District of Columbia have at least one registered ketamine therapy provider. The top 5 states by total provider count are California (389), Texas (376), Florida (274), New York (220), and Illinois (164).

# State Total Providers Spravato ASKP Per 1M Pop.
1 California 389 345 44 10.0
2 Texas 376 344 32 12.3
3 Florida 274 250 24 12.1
4 New York 220 208 12 11.2
5 Illinois 164 160 4 13.1
6 Ohio 154 148 6 13.1
7 New Jersey 135 129 6 14.5
8 Arizona 125 110 15 16.9
9 North Carolina 118 113 5 11.0
10 Virginia 112 105 7 12.9
11 Massachusetts 109 102 7 15.6
12 Tennessee 103 97 6 14.5
13 Maryland 95 93 2 15.3
14 Utah 95 92 3 27.9
15 Michigan 93 88 5 9.3
16 Washington 92 78 14 11.8
17 Colorado 89 68 21 15.1
18 Pennsylvania 89 82 7 6.9
19 Indiana 82 79 3 11.9
20 Georgia 76 68 8 6.9
21 Kansas 72 70 2 24.8
22 Missouri 72 71 1 11.6
23 Kentucky 70 69 1 15.6
24 Iowa 69 64 5 21.6
25 Nebraska 67 64 3 33.5
26 Oklahoma 64 62 2 15.6
27 Louisiana 61 59 2 13.3
28 Arkansas 61 60 1 19.7
29 Connecticut 61 57 4 16.9
30 Oregon 54 49 5 12.9
31 Minnesota 51 48 3 8.9
32 South Carolina 44 41 3 8.1
33 Nevada 42 39 3 13.1
34 Alabama 41 38 3 8.0
35 Idaho 40 34 6 20.0
36 Wisconsin 39 34 5 6.6
37 Mississippi 32 31 1 11.0
38 West Virginia 29 29 0 16.1
39 Montana 21 17 4 19.1
40 New Hampshire 21 20 1 15.0
41 Rhode Island 17 16 1 15.5
42 New Mexico 16 13 3 7.6
43 South Dakota 15 13 2 16.5
44 Maine 14 14 0 10.0
45 Delaware 13 11 2 13.0
46 Alaska 13 13 0 17.8
47 Wyoming 8 4 4 13.8
48 Vermont 6 4 2 9.2
49 District of Columbia 5 4 1 7.2
50 North Dakota 5 4 1 6.4
51 Hawaii 5 5 0 3.6

4. Clinic Density Per Capita

Adjusting for population reveals a different geographic picture. States with the highest per-capita provider density are not necessarily the most populous. Nebraska leads with 33.5 providers per million residents, followed by Utah (27.9) and Kansas (24.8).

National average density: 12.3 providers per million residents (based on estimated 2024 US population of 335 million)

# State Per 1M Residents Total Providers Population (est.)
1 Nebraska 33.5 67 2.0M
2 Utah 27.9 95 3.4M
3 Kansas 24.8 72 2.9M
4 Iowa 21.6 69 3.2M
5 Idaho 20.0 40 2.0M
6 Arkansas 19.7 61 3.1M
7 Montana 19.1 21 1.1M
8 Alaska 17.8 13 0.7M
9 Connecticut 16.9 61 3.6M
10 Arizona 16.9 125 7.4M
11 South Dakota 16.5 15 0.9M
12 West Virginia 16.1 29 1.8M
13 Oklahoma 15.6 64 4.1M
14 Massachusetts 15.6 109 7.0M
15 Kentucky 15.6 70 4.5M

The lowest-density states are Hawaii (3.6 per 1M), suggesting that geographic isolation and market size limit provider availability. Patients in low-density states may need to travel to access ketamine therapy or consider telehealth-based oral ketamine programs.

5. Top Cities by Provider Count

Major metropolitan areas concentrate the most providers. New York City leads with 46 providers, followed by Houston (43) and San Antonio (35).

# City Total Providers Spravato ASKP
1 Houston, TX 46 42 4
2 New York, NY 43 41 2
3 San Antonio, TX 35 33 2
4 Omaha, NE 31 30 1
5 Austin, TX 30 23 7
6 Chicago, IL 24 23 1
7 Phoenix, AZ 23 20 3
8 Dallas, TX 23 22 1
9 Las Vegas, NV 22 21 1
10 San Diego, CA 22 20 2
11 Miami, FL 21 19 2
12 Portland, OR 19 16 3
13 Tampa, FL 18 17 1
14 Tucson, AZ 18 17 1
15 Los Angeles, CA 17 16 1
16 Sacramento, CA 17 15 2
17 Tulsa, OK 17 17 0
18 Brooklyn, NY 17 17 0
19 Lincoln, NE 16 15 1
20 Gilbert, AZ 16 11 5

6. Provider Specialties

Of the 510 providers with NPI data available, the most common specialties are psychiatry, nurse practitioner (psychiatric), and anesthesiology. This reflects the multidisciplinary nature of ketamine therapy, which spans psychiatric, anesthesia, and primary care settings.

Specialty Count % of NPI-Verified
Psychiatry & Neurology, Psychiatry 141 27.6%
Nurse Practitioner, Psych/Mental Health 56 11.0%
Clinic/Center, Mental Health (Including Community Mental Health Center) 33 6.5%
Emergency Medicine 21 4.1%
Nurse Anesthetist, Certified Registered 18 3.5%
Anesthesiology 14 2.7%
Family Medicine 14 2.7%
Clinic/Center, Multi-Specialty 13 2.5%
Community/Behavioral Health 13 2.5%
Clinic/Center 10 2.0%

The presence of emergency medicine physicians (21) and family medicine practitioners (14) among ketamine providers indicates that ketamine therapy is not limited to psychiatric or anesthesia practices, though these remain the dominant specialties.

7. Data Source Overlap Analysis

The two primary data sources (Spravato REMS registry and ASKP directory) have limited overlap, indicating they capture distinct segments of the ketamine therapy market:

  • 3,816 providers (92.7%) appear only in the Spravato REMS registry — these are facilities certified to administer esketamine nasal spray but not ASKP members
  • 302 providers (7.3%) appear only in the ASKP directory — these typically focus on IV ketamine, IM ketamine, or KAP without Spravato certification
  • 0 providers (0.0%) appear in both sources — full-service ketamine clinics offering both Spravato and other ketamine modalities

The low overlap rate (0.0%) underscores that Spravato REMS centers and ASKP member clinics serve different market segments. Aggregating both sources is essential for a comprehensive picture of ketamine therapy availability in the United States.

8. How to Cite This Data

This data is published under a Creative Commons Attribution 4.0 (CC BY 4.0) license. You are free to share and adapt this data for any purpose, including commercial use, provided you give appropriate credit.

Suggested citation: DrugsRegistry.com. “Ketamine Therapy Clinics in the United States: 2026 Statistical Analysis.” Published April 16, 2026. https://drugsregistry.com/ketamine-clinics-statistics/. Accessed [date].

For researchers: This analysis is a dated snapshot compiled from the Spravato REMS and ASKP directories. ASKP is a voluntary membership directory, not a government registry, and every current status should be checked against the original source.

Data Sources

  1. Janssen Pharmaceuticals. Spravato treatment-center locator. official locator. Accessed July 2026; directory includes outpatient locations reporting treatment within the last six months.
  2. American Society of Ketamine Physicians, Psychotherapists, and Practitioners (ASKP). Member Provider Directory. official directory. Accessed July 2026.
  3. Centers for Medicare & Medicaid Services. National Plan and Provider Enumeration System (NPPES) NPI Registry. https://npiregistry.cms.hhs.gov/. Used for provider credential and specialty verification.
  4. U.S. Census Bureau. State Population Estimates, 2024. Used for per-capita density calculations.